Introduction
Inflammatory bowel disease (IBD) includes ulcerative colitis, Crohn's disease, and indeterminate colitis. It is a heterogeneous disorder with contributions from genetic background, microbiota, and other environmental factors. There has been a dramatic increase in the incidence of IBD over the past 50 years accompanied by a gradually decreasing median age of onset. At one time, the suspicion of primary immune deficiency disorder (PIDD) as a cause for IBD was low and restricted to patients with pediatric-onset and severe disease. With the changing epidemiology of IBD, it has become more difficult to define the population that would benefit from an evaluation for PIDD. This review will discuss the key clinical features of ulcerative colitis and Crohn's disease, the occurrence of PIDD in early-onset IBD, and the potential approaches for the diagnosis and management of such patients.
The Changing Epidemiology
Several large European cohorts have demonstrated a dramatic increase in incidence in IBD, but the findings are particularly notable for pediatric-onset Crohn's disease. In Scotland, there has been a 500% rise in pediatric Crohn's disease over the last 40 years with the most rapid rate of increase in just this past decade [1] . In Canada, one of the areas with the highest incidence of pediatric IBD, the most pronounced increase was seen in the very young children diagnosed less than five years of age, known as very early-onset IBD (VEO-IBD) [2] . There is a recognized North-South gradient with a higher incidence of IBD in the northern latitudes [3] . This North-South gradient is being altered, because developing countries have among the greatest increase in the rates of pediatric-onset IBD [4] . Other recognized epidemiologic features of IBD are familial This article is part of the Topical Collection on Immune Deficiency and Dysregulation occurrences. Fifteen to 20% of the patients with IBD will have a similarly affected family member, and for those patients with a pediatric presentation, 30% have a positive family history [5] . The risk of developing Crohn's disease in monozygotic twins is as high as 30-50% whereas the rate for dizygotic twins is only 2-4% [6, 7] . The most commonly identified genetic variants in genome-wide association studies for Crohn's disease are variants in the NOD2 (CARD15) gene [8•, 9] . This is in fact a mild immune deficiency with altered responses to muramyl dipeptide, a bacterial cell wall product [10] . Other common genetic variants that contribute to IBD include variants in genes related to autophagy, immune responses, and responses to the microbiome [11] . The major histocompatibility complex has also been frequently identified in genome-wide association studies, as is true for most autoimmune diseases. Genetic contributions to the etiology of IBD therefore are well established. Non-genetic contributors to the susceptibility to IBD are believed to include Western diet, obesity, dysbiosis of the gastrointestinal tract, sunlight exposure, and antibiotic use. The interplay between all of these identified epidemiologic associations is not well understood, and their specific contributions to the rising incidence of pediatric-onset IBD are not understood at all.
Clinical Features of IBD
Ulcerative colitis typically begins in the rectum and proceeds proximately, involving the mucosa in a symmetric uninterrupted pattern. The most common presenting symptoms are rectal bleeding, diarrhea, and abdominal pain. Pediatric cohort studies performed in the late 1990s demonstrated that 43% of the patients had mild disease at presentation, while 57% of the children had severe disease [12] . Patients with mild disease have limited systemic signs and negligible effects on nutrition. These patients typically respond well to therapy. Those who have moderate disease may have bloody diarrhea and abdominal tenderness. Weight loss, fever, anemia, and frequent cramps are common in this group. Severe colitis is seen in approximately 10% of the pediatric patients in which abdominal tenderness, fever, elevated inflammatory markers, and frequent bloody diarrhea are seen. These patients may have serious complications including hemorrhage, toxic megacolon, or perforation. Severity at presentation somewhat predicts the course. At 1 year following diagnosis, 1% of those with initial mild disease and 8% with moderate/severe required colectomy, and at 5 years, the risk of colectomy was 9 and 26% in the two groups, respectively [12] . A report of a regional incident cohort from Northern France in 2009 that included 113 pediatric patients showed progression from initial extensive disease in 37% at diagnosis to 60% by last follow-up and a cumulative colectomy rate of 20% by 5 years [13] . These studies demonstrate that while the presentation is modestly predictive of the ultimate course of disease, that overall morbidity is very high in early-onset IBD. A small fraction of patients will present with extra-intestinal manifestations, and those are described in Table 1 . Having one extraintestinal manifestation is a risk for additional extra-intestinal manifestations.
Crohn's disease can involve any portion of the gastrointestinal tract. The symptoms relate to the site of involvement, and small bowel involvement is often heralded by poor growth, weight loss, abdominal pain, and nutritional deficiencies [15] . Disease location and behavior are highly variable at diagnosis and are not fixed over time. Data from a large multicenter European registry found the initial disease location of 582 children with Crohn's disease to be widely distributed, and over time, disease extension was noted in 39% of the patients [16, 17] . Additionally, disease can present as an inflammatory phenotype and can progress to stricturing or penetrating disease over time [18] . The majority of children have involvement of the terminal ileum, and colonic involvement is most often in the ascending portion. Exclusive colonic disease is seen in 10-20% of the children, and this can cause confusion with the diagnosis of ulcerative colitis. Crohn's disease has a more variable presentation than ulcerative colitis, and it is not unusual for growth failure to precede the onset of frank gastrointestinal symptomatology by several years. Table 1 details common extra-intestinal manifestations of Crohn's disease. In some cases, these manifestations are synchronized with disease activity, whereas in others, they arise independently of gastrointestinal inflammation. In the case of Crohn's disease, key extra-intestinal features are skin tags, genital lymphedema, orofacial granulomatosis, or oral ulcers. Extra-intestinal manifestations were present in 20% of the children with IBD in a large European cohort [16] .
Indeterminate colitis refers to IBD in which the patient cannot be clearly assigned to either Crohn's disease or ulcerative colitis. This diagnostic category is more often seen in children than in adults, and over time, many patients will evolve more clearly into one or the other of the classical diagnoses [19•] .
PIDD Associated with IBD
There are now over 50 single gene or monogenic defects and a common polygenic PIDD associated with IBD [20, 21••] . The genes known to be associated with early-onset IBD are listed in Table 2 . Inclusion in this table requires more than a single case report of IBD in association with that specific immune deficiency. In the table, disorders in which IBD is likely to be a presenting manifestation are distinguished from those where IBD is more likely to arise later in the course. This distinction is useful, because it also defines a set of patients where infantile onset is seen versus those more likely to appear in later in childhood and adulthood. In large studies, the rate of monogenic disorders ranges from 10 to 20%. XIAP deficiency and IL-10 pathway defects have been most commonly reported [22] . Thus, they represent a minority of the cases; however, their distinct therapeutic requirements mandate that they be identified and managed according to the gene defect. As may be seen, a very broad range of types of immune deficiency can be associated with IBD. In certain cases, the pathophysiology is well understood whereas in others, there is limited understanding of the mechanism linking the immune deficiency with IBD. In general, susceptibility to IBD is thought to revolve around dysbiosis of the intestinal microbiota, breach of the intestinal epithelial layer, and aberrant regulation of host responses to bacteria. Encompassing these three broad tenets, a variety of patterns emerge. Dyskeratosis congenita, TTC7A mutations, trichohepatoenteric syndrome, and the ectodermal dysplasias may be seen as specific defects that impact the epithelial barrier function. Maintenance of the epithelial barrier requires contributions from innate lymphoid cells, and it may be that some immune deficiencies contribute to the pathogenesis of IBD through their effects on the innate lymphoid cell populations [23] . It is thought that many of the immune deficiencies impact the microbiota both by failing to tune the colonizing populations through immune responses and also due to frequent antibiotic use. Aberrant host responses to bacteria are a theme that links the IL-10 pathway and many of the antibody deficiencies. Nevertheless, these primary immune deficiencies probably have complex contributions to the susceptibility of IBD and therefore this reflects as incomplete penetrance of the IBD [24] . Only a very small number demonstrate rates of IBD in over half of the patients. This would include the IL-10 pathway defects, early-onset dyskeratosis congenita, the ectodermal dysplasias, and chronic granulomatous disease (in adults). Only the IL-10 pathway defects, trichohepatoenteric syndrome defects, and early-onset dyskeratosis congenita are likely to present with IBD.
Monogenic defects account for a minority of early-onset IBD. There may be clinical clues to help focus the work-up to identify those patients. Sequencing panels and whole exome sequencing represent the mainstays of the diagnostic approach; however, certain red flags in the history or pathology may allow the clinician to focus on higher risk cases. Infantile onset and association with other autoimmune disease represent historical features that may identify patients at high risk for monogenic diseases. Pathologic features that seem to associate with monogenic defects are high rates of apoptosis (seen in the dyskeratosis congenita defects and certain other PIDD), villous atrophy and increased intraepithelial lymphocytes (classically seen in immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX) and a subset of patients with common variable immunodeficiency), and a lymphocytic colitis (seen in some T cell defects). Pathologic features associated with chronic granulomatous disease are not consistent, but the Hermansky-Pudlak group of disorders has an association with pigmented macrophages [25•, 26-29] .
There are a number of monogenic defects that present classically with a malabsorptive picture. Congenital tufting enteropathy is an example. These disorders have a high rate of concomitant IBD, presumably on the basis of impaired barrier function. These conditions present nearly always in infancy with sever watery diarrhea, unresponsive to intake restrictions. Biopsies are most often characterized by a bland cellularity and pronounced villous atrophy. Diagnosis can be by characteristic pathology, special stains, or through genetic testing. A diagnostic approach to these children has been published [30] . 
Diagnosis of IBD
Diarrhea is a common symptom in patients with primary immune deficiency, and the natural inclination is to assume that the cause is infectious. Culture for Salmonella, Shigella, Campylobacter, and testing for Clostridium difficile toxin production is a common starting point. Parasitic infections should be sought specifically looking for Giardia, cryptosporidium, and Entamoeba. Other parasites and bacteria should be sought depending on their prevalence in the specific geographic area. Many immune deficient patients are also susceptible to viral infections, and for this reason, Epstein-Barr virus and CMV infections should be evaluated. In some settings, serologic testing for responses to Saccharomyces has been advocated. The serologic tests are thought to have limited sensitivity and specificity in patients with immune deficiency [31] . Initial blood tests should include a CBC and differential, serum albumin; C-reactive protein; and erythrocyte sedimentation rate. However, it is important to note that 21% of the children with mild Crohn's disease have normal results on all of these tests.
The preferred test to screen for intestinal inflammation is a fecal calprotectin level [32] . Magnetic resonance enterography is the imaging modality of choice for the detection of small intestine involvement [33•] . Wireless capsule endoscopy is a useful alternative; however, it cannot be used in the setting of small bowel narrowing. Additionally, some children cannot swallow the capsule, therefore it must be placed endoscopically [34] . Abdominal ultrasound may reveal large inflammatory masses, and some institutions utilize dedicated small bowel ultrasound to screen for small bowel disease. While used often in Europe, this use of ultrasound is limited to a few centers in the USA. The gold standard for the diagnosis of IBD is endoscopic visualization of the gastrointestinal tract and multiple biopsies, including intubation of the terminal ileum [33•] . Diagnostic biopsies must demonstrate evidence of chronic active changes in the small bowel and or colon (Fig. 1) .
Therapy of IBD in Patients with Primary Immune Deficiency
In general, therapy for IBD in patients with PIDD is not well established. The general goal for management should be to achieve clinical and laboratory control of the disease, optimization of growth and development, normalization of daily functioning, while minimizing side effects. Therapy often utilizes a rapid step-up approach, although the optimal strategy for patients with PIDD is not known. For mild ulcerative colitis and colonic Crohn's disease, mesalamine given as an oral drug, an enema, or a suppository can achieve adequate results. Steroid enemas are also frequently used in the setting of left-sided colonic disease. For patients with moderate ulcerative colitis, the strategies include antibiotics, mesalamine, and, in some cases, an induction regimen with oral steroids and then tapering once disease is in control. Patients who require steroids, however, are then likely to be initiated on immunomodulator therapy and or biologic therapy. Patients with mild-moderate Crohn's disease can be treated with nutritional therapy, which is probably underutilized but does have a very high response rate. As we understand more about how diet plays a role in the composition and function of the gut microbiota, and may be involved in the pathogenesis of the disease, it has become an obvious therapeutic target. Nutritional therapy can include total parenteral nutrition (TPN) and complete bowel rest (which is seldom used today) or enteral nutrition with a defined formula. TPN can achieve a response rates as high as 90% whereas enteral nutrition has remission rates between 50 and 80% after 4 weeks [35] [36] [37] . A number of defined diets have been used for the treatment of IBD. Exclusive enteral nutrition (EEN) has been extensively studied in pediatric IBD and has been shown to be effective in inducing and maintaining remission [38, 39] . Formula is the sole source of nutrition in this approach. There is no difference in efficacy between polymeric, semi-elemental, or elemental formulas. Partial EN has been shown to be effective as well, in which children receive 50-80% of the caloric requirements via formula and remaining of calories comes from food [40] . Other diets are utilized as therapy as well, including the specific carbohydrate free diet and the anti-inflammatory diet [41] . While nutritional therapy is more effective for Crohn's disease than ulcerative colitis, it can be an effective intervention for ulcerative colitis particularly in children who have poor nutrition. For those patients who have disease refractory to the previous interventions or who cannot be tapered from oral steroids, remission can be induced with immunomodulatory therapy (6-mercaptopurine, azathioprine, or methotrexate) or anti-TNF therapy. Safety remains a concern, and growing evidence has demonstrated an increased risk of malignancy with 6-mercaptopurine and azathioprine, particularly lymphomas [42] [43] [44] . Today, severe disease is most often treated with TNF inhibitors as a first choice, and in some centers, TNF inhibitors are used for moderate disease as well. Other therapeutic options now include anti-integrin (vedolizumab) and IL-12/IL-23 blockade with ustekinumab.
Therapy for patients with PIDD does have some recognized differences from therapy for IBD in the general population. A key consideration is that TNF inhibitors are associated with an unacceptable risk of serious fungal infections in patients with chronic granulomatous disease. Therefore, testing for chronic granulomatous disease should be performed before the initiation of TNF inhibitor use. It may be imagined that this high risk is also seen in the ectodermal dysplasias, but data are lacking. Some of the monogenic forms of humoral immunodeficiency can be treated with rapamycin, and LRBA deficiency may be treated with hydroxychloroquine. CTLA4 deficiency has been treated successfully with abatacept. One approach for therapy in patients with PIDD is to assess the character of the inflammatory infiltrate. When lymphocytic infiltrates are noted, particularly in the small bowel with villous atrophy, rapamycin is a more reasonable choice than a TNF inhibitor. T cell processes may also be treated with vedolizumab. Conversely when the inflammatory infiltrate is neutrophilic and limited to the colon, then a TNF inhibitor approach may be more likely to be beneficial.
The outcome for certain PIDD associated with IBD is poor, and therefore, bone marrow transplantation should be considered as a therapy. Although there are no hard and fast rules and donor availability represents a major contributor to the decision to proceed to transplant, chronic granulomatous disease, IPEX, IL-10 pathway defects, and all of the severe T cell deficiencies should have a consideration for bone marrow transplantation. Settings where transplantation does not seem to be warranted include those defects that are primarily driving epithelial defects such as trichohepatoenteric syndrome, Hirschsprung's disease, and severe dyskeratosis congenita.
Conclusions
Today, with a rapidly rising incidence of IBD, it is more difficult than ever to identify patients who have monogenic a b c d Fig. 1 PIDD. Patients who have infantile onset, atypical inflammatory infiltrates, and association with other autoimmune disease may have a PIDD. Management of patients can be exceedingly complex, and balancing the immune suppression with the underlying susceptibility to infection is often a challenge. Certain number of the monogenic defects can be approached with bone marrow transplantation, and this can be curative in those cases.
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